A5053487571- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Research Studies
- Childhood Cancer Survivors' Quality of Life
- Genomics and Chromatin Dynamics
- HER2/EGFR in Cancer Research
- Cardiac tumors and thrombi
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Chronic Lymphocytic Leukemia Research
Caris Life Sciences (United States)
2020-2025
Phoenix (United States)
2024
USA Mitchell Cancer Institute
2023
University of South Alabama
2023
Washington University in St. Louis
2023
University of Cincinnati
2023
Yahoo (United Kingdom)
2023
UC Davis Health System
2023
Sylvester Comprehensive Cancer Center
2023
University of Miami
2023
Previously, identification of promoters regulated by mammalian transcription factors has relied upon overexpression studies. Here we present the a large set that are bound E2F in physiological conditions. Probing human CpG microarray with chromatin immunoprecipitated using an antibody to E2F4, have identified 68 unique target loci; 15% bidirectional and 25% recruit via mechanism distinct from defined consensus site. Interestingly, although been shown previously regulate genes involved cell...
Using ChIP–chip assays (employing ENCODE arrays and core promoter arrays), we examined the binding patterns of three members E2F family in five cell types. We determined that most E2F1, E2F4, E2F6 sites are located within 2 kb a transcription start site, both normal tumor cells. In fact, majority promoters active (as defined by TAF1 or POLR2A binding) GM06990 B lymphocytes Ntera2 carcinoma cells were also bound an E2F. This very close relationship between for general factors suggests...
Obesity is associated with poorer outcome for many cancers. Previously, we observed that adipocytes protect acute lymphoblastic leukemia (ALL) cells from the anthracycline, daunorubicin. In this study, it determined whether clear daunorubicin tumor microenvironment (TME). Intracellular concentrations were evaluated using fluorescence. Daunorubicin and its largely inactive metabolite, daunorubicinol, analytically measured in media, cells, tissues liquid chromatography/mass spectrometry...
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Abstract A pediatric patient diagnosed initially with B‐lymphoblastic leukemia (B‐ALL) relapsed lineage switch to acute myeloid (AML) after chimeric antigen receptor T‐cell (CAR‐T) therapy and hematopoietic stem cell transplant. TCF3‐ZNF384 fusion was identified at diagnosis, persisted through B‐ALL relapse, also present in the AML relapse population. ZNF384‐rearrangements define a molecular subtype of characterized by pro‐B‐cell immunophenotype; furthermore, are prevalent mixed‐phenotype...
The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells in classic lymphoma (cHL) limits the ability to study genomics cHL. To circumvent this, our group has previously optimized fluorescence-activated cell sorting purify HRS cells. Using this approach, we now report whole-genome sequencing landscape reconstruct chronology likely etiology pathogenic events leading We identified alterations driver genes not described cHL, APOBEC mutational activity, presence complex structural variants...
Abstract Background Hepatotoxicity and pancreatitis are common treatment‐related toxicities (TRTs) during contemporary treatment regimens for acute lymphoblastic leukemia (ALL). Limited detailed data from Children's Oncology Group (COG) has been previously reported to enable identification of patient risk factors these their impact on outcomes. Procedure We analyzed a retrospective pediatric ALL cohort treated at single institution according COG 2008 2015. The primary endpoint was cumulative...
Abstract Background Tumors with homologous recombination deficiency (HRD) show high sensitivity to platinum salts and poly(ADP-ribose) polymerase–inhibitors in several malignancies. In colorectal cancer (CRC), the role of HRD alterations is mostly unknown. Methods Next-generation sequencing, whole transcriptome exome sequencing were conducted using CRC samples submitted a commercial Clinical Laboratory Improvement Amendments certified laboratory. pathogenic and/or presumed mutations 33 genes...
There is increasing evidence that adipocytes play an active role in the cancer microenvironment. We have previously reported interact with acute lymphoblastic leukemia (ALL) cells, contributing to chemotherapy resistance and treatment failure. In present study, we investigated whether part of this due adipocyte provision lipids ALL cells.We cultured 3T3-L1 adipocytes, tested cells or ALL-released cytokines induced FFA release. took up these FFA, using fluorescent tagged BODIPY-FFA...
Abstract Being overweight or obese (OW/OB) during B-cell acute lymphoblastic leukemia (B-ALL) induction is associated with chemoresistance as quantified by minimal residual disease (MRD). We hypothesized that caloric and nutrient restriction from diet/exercise could lessen gains in fat mass (FM) reduce postinduction MRD. The Improving Diet Exercise ALL (IDEAL) trial enrolled patients 10 to 21 years old, newly diagnosed B-ALL (n = 40), comparison a recent historical control 80). Designed...
We performed a retrospective analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site origin in cohort 143 cases. Primary sites were head neck (31%), breast (22%), extremity (11%), viscera (20%), skin at other locations (8%), unknown (9%). All cases had Next Generation Sequencing (NGS) data 592 gene panel, 53 Whole Exome (WES) data, which we used to study microenvironment phenotype. The immunotherapy (IO) response Tumor Mutation Burden (TMB), Microsatellite...
Cancer patients aged ≥80 years present unique characteristics affecting response to immune checkpoint inhibitors (ICIs), with unidentified molecular differences. This study aimed explore potential biomarkers of ICI in years. We analysed tumour samples (n=24 123) from (versus<80) non-small cell lung cancer (NSCLC), melanoma (MEL), and renal (RCC). Using gene expression deconvolution, we investigated differences microenvironment (TIME) composition. Then, using next-generation sequencing...
Babesia microti, an intraerythrocytic parasite, is tickborne in nature. In contrast to transmission by blood transfusion, which has been well documented, associated with solid organ transplantation not reported. We describe parasitologically confirmed cases of babesiosis diagnosed ≈8 weeks posttransplantation 2 recipients renal allografts from donor who was multiply transfused on the day he died traumatic injuries. The and had no identified risk factors for infection. Antibodies against B....
FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy oxaliplatin-based combined in mCRC.A machine-learning approach was applied tested on clinical next-generation sequencing data from real-world evidence (RWE) dataset samples the prospective TRIBE2 study resulting identification signature, FOLFOXai. Algorithm...
Urachal cancer, a rare malignancy, generally presents in the clinical setting with advanced stages of disease. Systemic treatment chemotherapy is utilized this setting. However, there remains paucity data on effectiveness immune checkpoint inhibitors or targeted therapies for urachal cancer. We analyzed genomic profile cancer order to identify potentially targetable mutations and evaluate tumor microenvironment. 42 samples were retrospectively analyzed. Our results showed that TP53, GNAS...
274 Background: BRAF mutations (mts) are a heterogeneous group of molecular alterations seen in colorectal cancer (CRC). Class I mts (V600) known to be associated with aggressive biology CRC, but the knowledge clinical characteristics class II and III is limited. In this large cohort analysis, we evaluated features performed comparative analyses for their impact on survival outcomes. Methods: A total 24402 MSS CRC samples were profiled by NGS (592-gene, NextSeq; WES, WTS NovaSeq) (Caris Life...